Concerns About Popular Weight Loss Medications
Medications like Zepbound and Wegovy, which many people use for weight loss, are showing some potential risks beyond just helping with slimming down. While these drugs can aid in losing weight, they also come with a range of side effects, such as nausea, vomiting, constipation, diarrhea, headaches, and skin reactions.
One alarming possibility relates to mental health. Reports suggest that around 10 million Americans are currently utilizing GLP-1 medications.
The Australian Medicines and Medical Devices Regulator (TGA) has issued warnings about the mental health risks associated with GLP-1 drugs, specifically linking them to suicidal thoughts and behaviors. This follows investigations prompted by a World Health Organization survey that highlighted concerns over the mental health of some users of weight-loss drugs.
In fact, the TGA recently recorded 72 instances of suicidal ideation, 6 related to suicide from depression, and 4 reports of attempts among users of GLP-1 drugs in September alone. While clear evidence connecting these drugs to such events is still lacking, the regulators are advising doctors to keep a close eye on any emerging or worsening mental health issues in patients.
On top of these mental health concerns, there’s also a warning regarding the effect of Munjaro on oral contraceptives, which may decrease their effectiveness. This aligns with earlier warnings from the UK’s Medicines and Healthcare Products Regulatory Agency regarding the use of tirzepatide, an ingredient in some weight-loss medications.
There is concern that all GLP-1 drugs, including Saxenda, Trulicity, and those based on semaglutide, like Ozempic or Wegovy, might carry similar risks. Earlier studies indicated that these weight-management drugs did not heighten the risk of depression or suicidal thoughts significantly.
Nonetheless, some health experts think that certain individuals might be more at risk for these mental health issues, particularly those with existing anxiety or depression histories. “It seems that patients with a background in mental health disorders might be more vulnerable,” suggests Terry Lynn South from the Royal Australian College of General Practitioners.
Interestingly, while there’s no evidence suggesting GLP-1 medications affect non-oral contraceptive methods like IUDs or implants, they can slow digestion, which impacts how oral contraceptives work. This slowing can hinder the absorption of these contraceptives, prompting experts to recommend additional preventive measures for those trying to avoid pregnancy.
For those taking tirzepatide and looking to prevent pregnancy, it is advised to use a backup method, like condoms, at least four weeks after increasing the medication dosage. Additionally, pregnant individuals should refrain from using weight-loss drugs due to insufficient safety data during pregnancy.
While some human studies indicate there may not be significant harm in early pregnancy, animal studies have raised alarms about possible risks for miscarriage and birth defects.
The recent TGA warnings are part of their ongoing safety monitoring, ensuring updates on the potential risks associated with weight-loss medications are communicated to healthcare professionals.
If anyone in New York City struggles with suicidal thoughts or a mental health crisis, they can reach out to 1-888-NYC-WELL for confidential support. For those outside the area, the National Suicide Prevention Hotline is available at 988, or you can visit SuicidePreventionLifeline.org.
